The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CHEMBL1264     1-[5-hydroxy-2-(2-hydroxy-3- propylamino...

Synonyms: SureCN2739132, CHEBI:343859, CTK8D6721, AR-1B9906, LS-186818, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of 5-Hydroxypropafenone

  • 4. Despite these changes in plasma concentrations, electrocardiographic intervals and arrhythmia frequency were unaltered by quinidine coadministration, indicating that 5-hydroxypropafenone contributes to the pharmacologic effects of propafenone therapy in extensive metabolizers [1].
  • The concentration of 5OHP needed to prevent ventricular fibrillation in 50% of experiments (EC50) was significantly higher than that of P (0.186 +/- 0.05 vs. 0.153 +/- 0.005 mg/L, mean +/- SEM, p less than 0.05) [2].
  • In summary, the disposition of propafenone and of its active metabolite 5-hydroxypropafenone was not affected by kidney dysfunction, indicating that no dose adjustment is necessary in patients with renal failure [3].
 

High impact information on 5-Hydroxypropafenone

 

Biological context of 5-Hydroxypropafenone

 

Anatomical context of 5-Hydroxypropafenone

 

Associations of 5-Hydroxypropafenone with other chemical compounds

 

Analytical, diagnostic and therapeutic context of 5-Hydroxypropafenone

References

  1. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Funck-Brentano, C., Kroemer, H.K., Pavlou, H., Woosley, R.L., Roden, D.M. British journal of clinical pharmacology. (1989) [Pubmed]
  2. The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model. Oti-Amoako, K., Vozeh, S., Ha, H.R., Follath, F. J. Cardiovasc. Pharmacol. (1990) [Pubmed]
  3. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Fromm, M.F., Botsch, S., Heinkele, G., Evers, J., Kroemer, H.K. Eur. J. Clin. Pharmacol. (1995) [Pubmed]
  4. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Botsch, S., Gautier, J.C., Beaune, P., Eichelbaum, M., Kroemer, H.K. Mol. Pharmacol. (1993) [Pubmed]
  5. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Zoble, R.G., Kirsten, E.B., Brewington, J. Clin. Pharmacol. Ther. (1989) [Pubmed]
  6. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Kroemer, H.K., Mikus, G., Kronbach, T., Meyer, U.A., Eichelbaum, M. Clin. Pharmacol. Ther. (1989) [Pubmed]
  7. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Arias, C., González, T., Moreno, I., Caballero, R., Delpón, E., Tamargo, J., Valenzuela, C. Cardiovasc. Res. (2003) [Pubmed]
  8. Propafenone and its metabolites preferentially inhibit IKr in rabbit ventricular myocytes. Cahill, S.A., Gross, G.J. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  9. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. Thompson, K.A., Iansmith, D.H., Siddoway, L.A., Woosley, R.L., Roden, D.M. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  10. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog. Boucher, M., Chassaing, C., Hamel, J.D., Poirier, J.M. Eur. J. Pharmacol. (1996) [Pubmed]
  11. Propafenone and 5-hydroxypropafenone concentrations in the right atrium of patients undergoing heart surgery. Latini, R., Barbieri, E., Castello, C., Marchi, S., Sica, A., Gerosa, G., Rossi, R., Zardini, P. Am. Heart J. (1989) [Pubmed]
  12. Tonic and phasic Vmax block induced by 5-hydroxypropafenone in guinea pig ventricular muscles. Valenzuela, C., Delpón, E., Tamargo, J. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  13. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. Ebner, T., Eichelbaum, M. British journal of clinical pharmacology. (1993) [Pubmed]
  14. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Bachmakov, I., Rekersbrink, S., Hofmann, U., Eichelbaum, M., Fromm, M.F. Naunyn Schmiedebergs Arch. Pharmacol. (2005) [Pubmed]
  15. Transient outward current inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes. Cahill, S.A., Kirshenbaum, L.A., Gross, G.J. J. Cardiovasc. Pharmacol. (2001) [Pubmed]
  16. Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers. Valenzuela, C., Delgado, C., Tamargo, J. J. Cardiovasc. Pharmacol. (1987) [Pubmed]
  17. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Kates, R.E., Yee, Y.G., Winkle, R.A. Clin. Pharmacol. Ther. (1985) [Pubmed]
  18. Determination of 5-hydroxypropafenone in biological fluids by fused-silica capillary gas chromatography using electron-capture detection. Chan, G.L., Axelson, J.E., Abbott, F.S., McErlane, K.M., Kerr, C.R. J. Chromatogr. (1989) [Pubmed]
  19. Enantioselective HPLC analysis of propafenone and of its main metabolites using polysaccharide and protein-based chiral stationary phases. Bonato, P.S., de Abreu, L.R., de Gaitani, C.M., Lanchote, V.L., Bertucci, C. Biomed. Chromatogr. (2000) [Pubmed]
  20. Internally standardized simultaneous assay of propafenone and 5-hydroxypropafenone enantiomers in human plasma by means of high performance liquid chromatography. Kern, R. Methods and findings in experimental and clinical pharmacology. (1994) [Pubmed]
 
WikiGenes - Universities